Colchicine : A potential therapeutic tool against COVID-19. Experience of 5 patients
Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved..
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Reumatologia clinica - 17(2021), 7 vom: 20. Aug., Seite 371-375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montealegre-Gómez, Giovanni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Completed 09.08.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.reumae.2020.05.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328462470 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328462470 | ||
| 003 | DE-627 | ||
| 005 | 20231225202955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.reumae.2020.05.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328462470 | ||
| 035 | |a (NLM)34301378 | ||
| 035 | |a (PII)S2173-5743(21)00133-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montealegre-Gómez, Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Colchicine |b A potential therapeutic tool against COVID-19. Experience of 5 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. | ||
| 520 | |a COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Colchicina | |
| 650 | 4 | |a Colchicine | |
| 650 | 4 | |a Inflamasoma | |
| 650 | 4 | |a Inflammasome | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Síndrome de distrés respiratorio agudo | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Tubulin Modulators |2 NLM | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 700 | 1 | |a Garavito, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-López, Arley |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas-Villarraga, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Parra-Medina, Rafael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reumatologia clinica |d 2011 |g 17(2021), 7 vom: 20. Aug., Seite 371-375 |w (DE-627)NLM213092891 |x 2173-5743 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:7 |g day:20 |g month:08 |g pages:371-375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.reumae.2020.05.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 7 |b 20 |c 08 |h 371-375 | ||